JPWO2019191264A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019191264A5
JPWO2019191264A5 JP2020552234A JP2020552234A JPWO2019191264A5 JP WO2019191264 A5 JPWO2019191264 A5 JP WO2019191264A5 JP 2020552234 A JP2020552234 A JP 2020552234A JP 2020552234 A JP2020552234 A JP 2020552234A JP WO2019191264 A5 JPWO2019191264 A5 JP WO2019191264A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
aqueous pharmaceutical
concentration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519321A5 (https=
JP2021519321A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024331 external-priority patent/WO2019191264A1/en
Publication of JP2021519321A publication Critical patent/JP2021519321A/ja
Publication of JP2021519321A5 publication Critical patent/JP2021519321A5/ja
Publication of JPWO2019191264A5 publication Critical patent/JPWO2019191264A5/ja
Abandoned legal-status Critical Current

Links

JP2020552234A 2018-03-27 2019-03-27 ペプチド含有製剤 Abandoned JP2021519321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648746P 2018-03-27 2018-03-27
US62/648,746 2018-03-27
PCT/US2019/024331 WO2019191264A1 (en) 2018-03-27 2019-03-27 Peptide-containing formulations

Publications (3)

Publication Number Publication Date
JP2021519321A JP2021519321A (ja) 2021-08-10
JP2021519321A5 JP2021519321A5 (https=) 2022-03-31
JPWO2019191264A5 true JPWO2019191264A5 (https=) 2022-03-31

Family

ID=66103053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552234A Abandoned JP2021519321A (ja) 2018-03-27 2019-03-27 ペプチド含有製剤

Country Status (11)

Country Link
US (1) US11517608B2 (https=)
EP (1) EP3773627A1 (https=)
JP (1) JP2021519321A (https=)
KR (1) KR20200139723A (https=)
CN (1) CN112040958A (https=)
AU (1) AU2019243724A1 (https=)
CA (1) CA3097341A1 (https=)
IL (1) IL277466A (https=)
MX (1) MX2020010085A (https=)
TW (1) TW202002996A (https=)
WO (1) WO2019191264A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
CN118236470A (zh) * 2024-03-29 2024-06-25 无锡市第二人民医院 MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
CN119241659B (zh) * 2024-10-08 2025-09-19 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
AU2008269954A1 (en) 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
WO2009135165A2 (en) 2008-05-01 2009-11-05 The Regents Of The University Of California Small humanin-like peptides
WO2012009709A1 (en) 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
TW201819398A (zh) * 2016-09-28 2018-06-01 美商寇峇有限公司 治療性肽

Similar Documents

Publication Publication Date Title
ES2405994T3 (es) Soluciones estabilizadas de teriparatide
TW434259B (en) Acylated insulin analogs
US20250064898A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
JP3295430B2 (ja) グルカゴンを含んでなる医薬製剤
JP2021519321A5 (https=)
JP5015411B2 (ja) 生体活性剤の改良された細胞取り込み
CN100475267C (zh) 含甘氨酸的高浓度人生长激素液体制剂
TW201127395A (en) Pharmaceutical composition comprising a GLP-1 agonist and methionine
TW201105346A (en) Heat-stable and vibration-stable insulin preparations
JPH02101022A (ja) 糖尿病治療用医薬組成物
JPH0925238A (ja) 経鼻投与用製剤
CN103338790A (zh) 用聚乙二醇或其衍生物聚乙二醇化的唾液素-4类似物、其制备方法以及含有其作为活性成分的用于预防或治疗糖尿病的药物组合物
CN114796462A (zh) 一种长效glp-1衍生物的药物制剂
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
JP7060589B2 (ja) ポリエチレングリコールロキセナチドを含有する薬物製剤及びその製造方法
TWI247608B (en) Growth hormone formulations
US20190060410A1 (en) Pharmaceutical Formulation Comprising GLP-1 Analogue and Preparation Method Thereof
JP2014515747A (ja) 医薬組成物
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
JPWO2019191264A5 (https=)
JPWO2020065064A5 (https=)
CN102133200B (zh) 一种人类松弛素-2 Relaxin的注射用冻干粉制剂
CN102342931A (zh) 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
AU2009218060B2 (en) Pharmaceutical composition for transnasal administration
CN102283818A (zh) 多肽和蛋白质类药物口服肠溶胶囊及其制备方法